Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial

• Published in: BMJ open diabetes research & care Vol. 4; no. 1; p. e000190
• Main Authors: Matsushima, Yukiko, Takeshita, Yumie, Kita, Yuki, Otoda, Toshiki, Kato, Ken-ichiro, Toyama-Wakakuri, Hitomi, Akahori, Hiroshi, Shimizu, Akiko, Hamaguchi, Erika, Nishimura, Yasuyuki, Kanamori, Takehiro, Kaneko, Shuichi, Takamura, Toshinari
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 2016; BMJ Publishing Group
• Subjects: Clinical Care/Education/Nutrition/Psychosocial Research; A1C; Drug Therapy; Fatty Acid Desaturase(s)
• ISSN: 2052-4897; 2052-4897
• DOI: 10.1136/bmjdrc-2015-000190

PurposeA step-up strategy for diet therapy and/or single oral antihyperglycemic agent (OHA) regimens has not yet been established. The aim of this study was to evaluate hemoglobin A1c (HbA1c) as a primary end point, and the pleiotropic effects on metabolic and cardiovascular parameters as secondary end points, of sitagliptin versus voglibose in patients with type 2 diabetes with inadequate glycemic control while on diet therapy and/or treatment with a single OHA.MethodsIn this multicenter, randomized, open-label, parallel-group trial, a total of 260 patients with inadequately controlled type 2 diabetes (HbA1c levels >6.9%) were randomly assigned to receive either sitagliptin (50 mg, once daily) or voglibose (0.6 mg, thrice daily) for 12 weeks. The primary end point was HbA1c levels.ResultsPatients receiving sitagliptin showed a significantly greater decrease in HbA1c levels (−0.78±0.69%) compared with those receiving voglibose (−0.30±0.78%). Sitagliptin treatment also lowered serum alkaline phosphatase levels and increased serum creatinine, uric acid, cystatin-C and homeostasis model assessment-β values. Voglibose increased low-density lipoprotein-cholesterol levels and altered serum levels of several fatty acids, and increased Δ-5 desaturase activity. Both drugs increased serum adiponectin. The incidence of adverse events (AEs) was significantly lower in the sitagliptin group, due to the decreased incidence of gastrointestinal AEs.ConclusionsSitagliptin shows superior antihyperglycemic effects compared with voglibose as a first-line or second-line therapy. However, both agents possess unique pleiotropic effects that lead to reduced cardiovascular risk in Japanese people with type 2 diabetes.Trial registration numberUMIN 000003503.